Browse Learn
Drug patents and exclusivity, explained
How long can one company sell a new medicine without a generic or biosimilar competitor? The answer depends on two different systems: patents and regulatory exclusivity. Here is how they work in the United States and Europe.
1. What is the difference between a patent and exclusivity?
A patent is a legal right that can stop others from making, using or selling an invention without permission. A drug company may patent a new molecule, a manufacturing method or a particular way to use a medicine. In the US, the ordinary patent term is generally 20 years from filing—not 20 years from drug approval. Because testing a drug takes years, some patent life may be used before the product reaches patients.[1]
Regulatory exclusivity is different: it comes from drug-approval laws, usually starts at approval and limits when FDA can accept or approve certain competing applications. A patent and an exclusivity period can overlap, end on different dates, and protect different things. Neither should be read as a promise that a company will face no competition.[1]
Protects an invention
Granted by a patent office. Usually measured from the filing date.
Often 20 years from filingProtects an approval pathway
Granted under drug laws. Generally measured from a product's approval date.
Length depends on eligibility2. Small molecules versus biologics: why does it matter?
Small-molecule medicines are usually made by chemical reactions and often come as tablets or capsules. Their follow-on competitors are called generics. Biologics, such as many antibodies, are often large, complex products made using living cells. Their follow-on products are called biosimilars, because manufacturing an exact copy is generally not possible in the same way as for a simple chemical molecule.[2]
US law gives these product types different approval pathways and different standard exclusivity periods. The easiest memory aid is Orange Book for many conventional drugs; Purple Book for biological products. There are exceptions, so approval classification—not whether a company calls itself “biotech”—determines the system.[2]
Made mainly by chemistry
Follow-on: generic drug
FDA reference: Orange Book
Often produced by living cells
Follow-on: biosimilar
FDA reference: Purple Book
3. What are the Orange Book and Purple Book?
The FDA's Orange Book is a searchable list of approved drug products and related information, including certain listed patents and regulatory exclusivity. A company studying a generic competitor may look here to see relevant patents and their expiration dates. But the list is not a court judgment that every listed patent is valid or blocks competition.[3]
The FDA's Purple Book lists licensed biological products, including reference products and biosimilars, plus applicable exclusivity information. Its patent-information system differs from the Orange Book. Knowing which book to check is a first step—not a complete freedom-to-operate analysis.[4]
Drug products
Approved medicines, therapeutic equivalence evaluations, relevant listed patents and exclusivity.
Explore Orange Book ↗Biological products
Reference biologics, biosimilar and interchangeable licenses, and reference-product exclusivity.
Explore Purple Book ↗4. How long does US regulatory exclusivity last?
The FDA offers several kinds of protection. A qualifying new chemical entity can receive five years of exclusivity, while a new clinical investigation supporting certain changes to an existing drug can qualify for three years. US orphan-drug exclusivity is generally seven years for the protected use. A qualifying reference biologic receives 12 years before biosimilar approval can become effective, although a biosimilar application can usually be submitted after four years. These periods have different rules and exceptions.[1][4]
For some drugs, pediatric studies requested by FDA can add six months to existing protection. This is not a general six-month reward for every children's medicine. The bars below compare selected standard durations, not the total time a specific medicine will be protected.
5. Can a patent last longer because FDA approval took years?
Yes. Patent term extension (also called patent term restoration) may give back some of the patent time lost during drug testing and FDA review. The Hatch-Waxman rules generally count half of an eligible testing period plus the eligible approval-review period, with adjustments, including for delays attributable to lack of due diligence. An extension cannot normally exceed five years, or leave more than 14 years of patent life after approval. Only one patent may be extended for a given product's regulatory review period.[5]
Suppose a drug spent six eligible years in clinical testing and two years in FDA review. The starting calculation is three years plus two years: five years. But that is only an illustration. A real result depends on when the patent issued, its unextended expiration, eligible review dates and legal limits. A patent owner generally must apply within 60 days after qualifying FDA approval.[5]
6. How does drug protection work in Europe?
The European Union has its own system. A medicine normally needs a marketing authorisation before sale. For many biotech drugs and certain other medicines, companies apply through the European Medicines Agency (EMA), with an EU-wide authorisation granted by the European Commission. Other medicines may use national or coordinated national procedures. EU clinical-trial applications can be handled through a shared system called CTIS, but national authorities still assess and supervise trials.[6]
Under the framework in use before the latest reform takes effect, many new medicines receive eight years of regulatory data protection, followed by two years of market protection, with a possible extra year for a qualifying new use: often called 8 + 2 + 1. Separately, a Supplementary Protection Certificate (SPC) may extend certain patent rights by up to five years, with a possible six-month pediatric extension if conditions are met.[7][8]
7. When can a generic or biosimilar enter the market?
There is no single “patent cliff” date that fits every drug. A competitor needs its own regulatory approval, must navigate applicable exclusivity, and must address any patents that could lawfully prevent launch. Some patents can be challenged, some cover only specific uses or formulations, and others expire well after the earliest exclusivity period. A brand company's forecasted loss of exclusivity can therefore be uncertain.[1][3]
For a practical first look, check the approval date, the product's FDA pathway, the applicable Orange Book or Purple Book information, the patent claims and expiration dates, and pending litigation. Regulatory clearance and the right to commercialize without infringing patents are different questions.
Sources & further reading
Primary regulators and statutory text; the explanations and teaching examples above are simplified for general education. Rules and dates may change.
- FDA — Frequently Asked Questions on Patents and Exclusivity.
- Congressional Research Service — Hatch-Waxman and Biologics Competition.
- FDA — Orange Book.
- FDA — Purple Book and Reference Product Exclusivity.
- 35 U.S.C. § 156 — Patent Term Extension; USPTO explanation.
- EMA — Clinical Trials Regulation.
- EMA — Pre-authorisation Guidance (8+2+1).
- European Commission — Supplementary Protection Certificates.
- Council of the EU — Pharmaceutical Reform, status and timetable.
Continue learning
Explore the science behind different drug types, then see how development risk and exclusivity feed into a valuation.
Educational content, not investment advice. Terms